Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 57
- Registration Number
- NCT01518699
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
Effect of Liraglutide on Heart Frequency in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT01516255
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Fargo, North Dakota, United States
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- XenoPort, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01516372
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01514929
- Locations
- 🇺🇸
Investigational Site, West Bend, Wisconsin, United States
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)
- Conditions
- Interventions
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Knopp Biosciences
- Target Recruit Count
- 68
- Registration Number
- NCT01511029
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 60
- Registration Number
- NCT01487135
A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart
- Conditions
- Interventions
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 67
- Registration Number
- NCT01460368
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2011-10-19
- Lead Sponsor
- Ophthalmology Consultants, Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT01455233
- Locations
- 🇺🇸
Ophthalmology Associates, St. Louis, Missouri, United States
🇺🇸Ophthalmology Consultants, Ltd, St. Louis, Missouri, United States
To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT01449188
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2015-10-29
- Target Recruit Count
- 218
- Registration Number
- NCT01423916
- Locations
- 🇺🇸
Otsuka Investigational Site, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.